Description
Background:
Gresonitamab is an IgG-1 T cell engaging bispecific antibody directed against the tumor-associated antigen (TAA) claudin. It simultaneously binds CLDN18 and CD3e, and is currently being investigated for its therapeutic effects on gastroesophageal junction adenocarcinoma.
Intended Use:
For Estimation of Gresonitamab in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us for optimisation.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!